报批美国FDA仿制药研发与相关问题探讨-Final.ppt

报批美国FDA仿制药研发与相关问题探讨-Final.ppt

《报批美国FDA仿制药研发与相关问题探讨-Final.ppt》由会员分享，可在线阅读，更多相关《报批美国FDA仿制药研发与相关问题探讨-Final.ppt（40页珍藏版）》请在冰点文库上搜索。

开发报批美国FDA的仿制药与相关问题探讨,上海复星普适医药科技有限公司何平,内容提要,开发仿制药的重要性和机遇开发仿制药的挑战申报仿制药的分类仿制药研发团队仿制药的研发过程QbD在制剂开发中怎么体现研发（高难）仿制药的一些体会：

案例研究,开发仿制药的重要性,新药与仿制药-NDAandANDA开发仿制药与我国药物研发的海外战略,药物制剂目标主流市场,开发仿制药的挑战性,开发仿制药更具挑战性药物制剂专利仿制药的竞争仿制药厂之间的竞争由品牌药转成仿制药,仿制药竞争的方式HOWTOCOMPETE,Cost-IRProductRawMaterialsProcessFinishedProductTechnology-ModifiedReleaseProducts,申报（仿制）新药的分类,规范市场（FDA）1。

P-I2。

P-II3。

P-III4。

P-IV（1sttofile）,中国市场（sFDA）1类2类3类4类5类6类,仿制药研发团队CONCEPT-1BUILDUPATEAM,REGULATORY,DRUGDELIVERYSYSTEMSFORORALSOLIDFORMULATIONS-MRMATRIXSYSTEMSRESERVIORSYSTEMSOSMOTICALPUMPSYSTEMSCOMBO-SYSTEMS,缓控释给药的技术平台和给药系统CONCEPT-2BUILDUPASYSTEM,ProductDevelopmentRoadmap仿制药的研发过程,QualityAcceptablylowriskoffailingtoachievethedesiredclinicalattributesPharmaceuticalQuality=fdrugsubstance,excipients,manufacturing.QbDProductandprocessperformancecharacteristicsscientificallydesignedtomeetspecificobjectives,notmerelyempiricallyderivedfromperformanceoftestbatches,WhatisQbD（QualitybyDesign）?

QbD在制剂开发中怎么体现？

WhatisQbD?

QbD在制剂开发中怎么体现？

PharmaceuticalQualitybyDesign（QbD）QbDmeansdesigninganddevelopingformulationsandmanufacturingprocessestoensurepredefinedproductqualityUnderstandingandcontrollingformulationandmanufacturingprocessvariablesaffectingthequalityofadrugproduct,EssentialelementsofQbDDefinitionofthequalitytargetproductprofileHighlevelqualityaspectsoftheproduct:

purity,drugrelease（dissolution/disintegrationtime）,pharmacokineticprofile,etc.Criticalqualityattributes（CQAs）fordrugproductCharacteristicsofDPwhichhaveimpactondesiredprofileConsciousattempttostudyandcontrolCriticalProcessParameters（CPPs）IdentificationofmaterialpropertiesandprocessparameterswhichhaveeffectonproductCQAsDesignSpace:

ThemultidimensionalcombinationandinteractionofinputvariablesandprocessparametersthathavebeendemonstratedtoprovideassuranceofqualityIdentificationofacontrolstrategyforcriticalprocessparameters,WhatisQbD?

QbD在制剂开发中怎么体现？

RawMaterials,Equipment,Environment,Operators,VariableInputs,x,“Locked”Process,=,VariableQuality,HowDidWeWorkinthePast,WhatisQbD?

QbD在制剂开发中怎么体现？

RawMaterials,Equipment,Environment,Operators,UnderstoodVariableInputs,x,UnderstoodandControlledProcess,=,PredefinedQuality,FlexibleProcessDesignSpace,HowCanWeWorkintheFuture,WhatisQbD?

QbD在制剂开发中怎么体现？

WhatisQbD?

QbD在制剂开发中怎么体现？

RawMaterials,WetGranulation,FluidBedDrying,Blending,Compression,Product,DrugSubstance,Excipients,SourceAssayImpuritiesLODPS,WhatisQbD?

QbD在制剂开发中怎么体现？

WaterBinderTempSprayRateSpeedTimeP.S,WhatisQbD?

QbD在制剂开发中怎么体现？

WhatisQbD?

QbD在制剂开发中怎么体现？

AirFlowTempRHShockCycleP.S.,WhatisQbD?

QbD在制剂开发中怎么体现？

FillVolumeRotationSpeedEndPoint（Time）BlendUniformityDensitiesAngleofRepose,WhatisQbD?

QbD在制剂开发中怎么体现？

FeedFrameToolingPunchPenetrationDepthCompressionForcePressSpeedFeederSpeed,QualityAssessmentunderQbR,Question-basedReview（QbR）isageneralframeworkforascienceandrisk-basedassessmentofproductqualityQbRcontainstheimportantscientificandregulatoryreviewquestionstoComprehensivelyassesscriticalformulationandmanufacturingprocessvariablesSetregulatoryspecificationsrelevanttoqualityDeterminethelevelofriskassociatedwiththemanufactureanddesignoftheproduct,ExamplesofQbDquestionsunderQbRControlofDrugSubstanceWhatisthedrugsubstancespecification?

Doesitincludeallthecriticaldrugsubstanceattributesthataffectthemanufacturingandqualityofthedrugproduct?

（2pages）DrugProductWhatattributesshouldthedrugproductpossess?

（1.5pages）Howweretheexcipientsandtheirgradesselected?

Howwasthefinalformulationoptimized?

ManufacturingProcessHowarethemanufacturingsteps（unitoperations）relatedtothedrugproductquality?

Howwerethecriticalprocessparametersidentified,monitored,and/orcontrolled?

PharmaceuticalDevelopmentManufactureContainerClosureSystem,QbD小结-SUMMARY,研发（高难）仿制药的一些体会,案例研究-1CASESTUDY1-IRTablets,VeryLowWaterSolubility（低水溶性）VeryLowPotency（低剂量）MicronizedAPIused（微粉化原料药）WetGranulationProcess（湿法制粒）,DissolutionProfile-体外溶出曲线,生物等效（BE）结果,SummaryofinvivostudyresultsofTestFormulationvs.RLD,原因调查,案例研究-2CASESTUDY2-ERCAPSULES,NoPatent（无专利）CoatedPellets（包衣微丸）1stBioStudyFailedFast:

CloseFed（ComparedwithFast）:

Brand:

BAReducedTested:

BAIncreased,TEAMWORK,MoreInformationCollectedAnalyticalSupportIdentifytheProcessUsedProvidetheInfoforFunctionalCoatingOnemorePilotandOneFullBio-Passed,案例研究-3CASESTUDY3-ERCAPSULES,BrandProductMicro-TabletsinCapsules95%ofAPIexistedinFinishedProductSystemandProcessPatented,UNIQUESYSTEM-CREATIVEDESIGN,CompressedGranulesinCapsulesRequirementSameDissolutionBehaviorUniformYieldAcceptable,SYSTEMCOMPARISON,PILOTBIO-STUDY,PRODUCTPDATA（LogTransformedData,Fast,n-12）,PILOTBIO-STUDY,PRODUCTPDATA（LogTransformedData,FED,n-11）,PIVOTALBIO-STUDY,PRODUCTPDATA（LogTransformedData）,案例研究-4CASESTUDY4-ERCAPSULES,APIisWaterSoluble.Prototypeformulationwasproposedbasedoninvitrodissolution（OGDmethod）.,PILOTBIO-STUDY,PRODUCTDATA（LogTransformedData）,FurtherInvestigation,谢谢!

139-1866-,